Intellia Therapeutics, Inc. is undergoing strategic reorganization, halting NTLA-3001, and reducing workforce by 27% to extend cash runway into 2027, focusing on late-stage programs NTLA-2002 and Nexi...

On Thursday, Intellia Therapeutics Inc NTLA outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z.

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell ane...

NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most...

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month'...

Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside poten...

Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communication...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.38 per share a year ago.

There's nothing bearish at all about what it reported recently.

Maybe the Street is a bit too optimistic on this one.

These 12 innovative companies could deliver exponential returns over the next quarter century.

Intellia Therapeutics, Inc. achieved positive phase 1/2 results using NTLA-2002 for HAE patients: 8 out of 11 patients taking higher doses of 50 mg of NTLA-2002 were attack-free during the 16-week pri...

Seemingly encouraging results from the lab were met with some notable skepticism.

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corp...

The ever-volatile biotech sector is making noise today.